Medical Responsible
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · EMD Serono Research & Development Institute, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Medical Responsible as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Showing 200 of 330. Open this list on ClinicalTrials.gov
- Ph1NCT07850635 · A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · not yet recruiting · Neurofibromatosis Type 1-Associated Plexiform Neurofibromas · study director
- Ph1NCT07840612 · A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · recruiting · Healthy · study director
- Ph3NCT07840287 · A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]EMD Serono Research & Development Institute, Inc. · recruiting · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) · study director
- Ph3NCT07549412 · A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)EMD Serono Research & Development Institute, Inc. · recruiting · Metastatic Colorectal Cancer · study director
- Ph2NCT07499362 · Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · recruiting · Tenosynovial Giant Cell Tumor · study director
- Ph1NCT07360314 · Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · recruiting · Advanced Solid Tumors · study director
- Ph3NCT07355218 · A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)EMD Serono Research & Development Institute, Inc. · recruiting · Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus · study director
- Ph3NCT07340827 · A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · recruiting · Infertility · study director
- Ph3NCT07332481 · A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc. · recruiting · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) · study director
- Ph1NCT07269327 · An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian OriginMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Fertility · study director
- Ph1NCT07215806 · Effect of Evobrutinib on Pharmacokinetics of a Combined Oral ContraceptiveMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT07214935 · A TQT Study of Effect of M2951 on Cardiac RepolarizationMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT07214922 · Relative Bioavailability of Evobrutinib Tablet BatchesMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph4NCT07176689 · Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · recruiting · Desmoid Tumor, Aggressive Fibromatosis · study director
- Ph2NCT07170644 · A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · active not recruiting · Desmoid Tumor, Aggressive Fibromatosis · study director
- Ph1NCT07166601 · M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · recruiting · Advanced Solid Tumor · study director
- Ph1NCT07097259 · A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male ParticipantsEMD Serono Research & Development Institute, Inc. · completed · Hypogonadism · study director
- Ph1NCT06997276 · Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · recruiting · Healthy, Hepatic Impairment · study director
- Ph1NCT06806046 · Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · active not recruiting · Solid Tumors, Colorectal Cancer · study director
- Ph1NCT06719973 · Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)EMD Serono Research & Development Institute, Inc. · withdrawn · Advanced Solid Tumors · study director
- Ph1/Ph2NCT06710132 · Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)EMD Serono Research & Development Institute, Inc. · active not recruiting · Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC) · study director
- Ph1NCT06641908 · Anti-GD2 ADC M3554 in Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · recruiting · Advanced Solid Tumor · study director
- Ph1NCT06589713 · Effect of Renal Impairment on Enpatoran PharmacokineticsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Renal Impairment · study director
- Ph1NCT06589726 · A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT06577337 · Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · suspended · Healthy · study director
- Ph1NCT06509906 · M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)EMD Serono Research & Development Institute, Inc. · terminated · Advanced Solid Tumor · study director
- Ph3NCT06463587 · Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · recruiting · Generalized Myasthenia Gravis · study director
- Ph2NCT06433219 · Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)EMD Serono Research & Development Institute, Inc. · completed · Ovarian Cancer · study director
- Ph2NCT06424717 · Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)EMD Serono Research & Development Institute, Inc. · withdrawn · Urothelial Carcinoma · study director
- Ph1NCT06421935 · M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)EMD Serono Research & Development Institute, Inc. · active not recruiting · Advanced Solid Tumor · study director
- N/ANCT06412848 · JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment StudyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Urothelial Carcinoma · study director
- Ph1NCT06308263 · Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Solid Tumor · study director
- Ph1NCT06251310 · SW-682 in Advanced Solid TumorsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · recruiting · Advanced Solid Tumor, Mesothelioma, Malignant · study director
- Ph1NCT06056310 · Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)EMD Serono Research & Development Institute, Inc. · terminated · Head and Neck Cancer · study director
- Ph2NCT05974267 · Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Malaria Infection · study director
- Ph1NCT05930808 · Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1/Ph2NCT05882734 · Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)EMD Serono Research & Development Institute, Inc. · completed · Non-Small Cell Lung Cancer · study director
- N/ANCT05797740 · Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · active not recruiting · Multiple Sclerosis · study director
- Ph2NCT05689047 · Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Acute Malaria · study director
- N/ANCT05655832 · A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPDMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Pulmonary Disease, Chronic Obstructive · study director
- Ph2NCT05650567 · Study of M5049 in DM and PM Participants (NEPTUNIA)EMD Serono Research & Development Institute, Inc. · terminated · Dermatomyositis, Polymyositis · study director
- N/ANCT05650164 · Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Renal Cell Carcinoma · study director
- Ph2NCT05540327 · The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · active not recruiting · Systemic Lupus Erythematosus · study director
- Ph1NCT05519540 · PK Study of Xevinapant (Debio 1143) in Healthy East Asian ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05464030 · Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)EMD Serono Research & Development Institute, Inc. · active not recruiting · Colorectal Cancer · study director
- Ph1NCT05463094 · GXR RM China BE Study (Darmstadt - Jiangsu)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- N/ANCT05431777 · A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has SpreadMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Urothelial Carcinoma · study director
- Ph1NCT05396833 · Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)EMD Serono Research & Development Institute, Inc. · completed · Metastatic or Locally Advanced Unresectable Solid Tumors · study director
- Ph3NCT05386550 · Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)EMD Serono Research & Development Institute, Inc. · terminated · Head and Neck Cancer · study director
- N/ANCT05376891 · Met Non Small Cell Cancer Registry (MOMENT)EMD Serono Research & Development Institute, Inc. · recruiting · Cancer · study director
- N/ANCT05366725 · A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After ChemotherapyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Urothelial Cancer · study director
- Ph2NCT05348356 · Nirogacestat in Ovarian Granulosa Cell TumorsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · completed · Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer · study director
- Ph2NCT05327530 · A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)EMD Serono Research & Development Institute, Inc. · active not recruiting · Locally Advanced or Metastatic Urothelial Carcinoma · study director
- Ph1NCT05248945 · DDI Study of Evobrutinib and CarbamazepineMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05246111 · Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Advanced Solid Tumor · study director
- Ph1NCT05245396 · Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05213481 · Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05203822 · Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05198349 · First in Human Study of M1069 in Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · terminated · Metastatic or Locally Advanced Unresectable Solid Tumors · study director
- Ph1NCT05174000 · BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT05162586 · The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)EMD Serono Research & Development Institute, Inc. · completed · Systemic Lupus Erythematosus · study director
- Ph1NCT05110027 · Enpatoran Human Mass Balance and Absolute Bioavailability StudyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT05081180 · Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsEMD Serono Research & Development Institute, Inc. · terminated · Central Nervous System Tumors · study director
- Ph1NCT05064488 · Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph3NCT05061823 · Bintrafusp Alfa Program Rollover StudyEMD Serono Research & Development Institute, Inc. · completed · Lung Cancer, Cancer · study director
- N/ANCT04997148 · Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Relapsing-Remitting Multiple Sclerosis · study director
- N/ANCT04941768 · An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Carcinoma, Renal Cell · study director
- N/ANCT04934800 · Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Multiple Sclerosis · study director
- N/ANCT04907305 · Next-Gen MS: Feed-forward PRO Data for MS ResearchEMD Serono Research & Development Institute, Inc. · terminated · Multiple Sclerosis (MS) · study director
- Ph1NCT04899193 · Pergoveris FD and Liquid China BE StudyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04882917 · First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)EMD Serono Research & Development Institute, Inc. · completed · Advanced Solid Tumors · study director
- Ph1NCT04880213 · Study of M5049 in Healthy Japanese and Caucasian ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph4NCT04783935 · Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Multiple Sclerosis · study director
- Ph4NCT04776213 · Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Multiple Sclerosis · study director
- Ph2NCT04768296 · Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)EMD Serono Research & Development Institute, Inc. · completed · Small-cell Lung Cancer · study director
- N/ANCT04735406 · The MS-LINK™ Outcomes StudyEMD Serono Research & Development Institute, Inc. · completed · Multiple Sclerosis · study director
- Ph1NCT04702698 · Effect of Food on Peposertib PKMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04697511 · Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04695847 · M1231 in Participants With Solid TumorsEMD Serono Research & Development Institute, Inc. · completed · Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer · study director
- Ph1NCT04684420 · GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) StudyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1/Ph2NCT04655183 · Study of M4344 in Combination With NiraparibEMD Serono Research & Development Institute, Inc. · withdrawn · Advanced Solid Tumor, Breast Cancer · study director
- Ph1NCT04647708 · Study of M5049 in CLE and SLE ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus · study director
- Ph1NCT04551950 · Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)EMD Serono Research & Development Institute, Inc. · completed · Cervical Cancer · study director
- Ph1NCT04546789 · Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Hepatic Impairment · study director
- Ph2NCT04515394 · Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)EMD Serono Research & Development Institute, Inc. · terminated · Colorectal Neoplasms · study director
- Ph2NCT04489940 · Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast CancerEMD Serono Research & Development Institute, Inc. · terminated · Triple Negative Breast Neoplasms · study director
- Ph1NCT04457778 · First in Human Study of M6223EMD Serono Research & Development Institute, Inc. · completed · Metastatic Solid Tumors · study director
- Ph3NCT04459715 · A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)EMD Serono Research & Development Institute, Inc. · terminated · Squamous Cell Carcinoma of the Head and Neck · study director
- Ph2NCT04448756 · Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)EMD Serono Research & Development Institute, Inc. · completed · Coronavirus Disease 2019 · study director
- Ph3NCT04338022 · Study of Evobrutinib in Participants With RMS (evolutionRMS 1)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · terminated · Relapsing Multiple Sclerosis · study director
- Ph3NCT04338061 · Study of Evobrutinib in Participants With RMS (evolutionRMS 2)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · terminated · Relapsing Multiple Sclerosis · study director
- Ph1NCT04314024 · Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial TabletsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04314037 · Bioequivalence Study of Coated Cesol Tablet Formulation Versus BiltricideMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04250363 · Chemoprophylactic Activity of M5717 in PfSPZ Challenge ModelMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT04246489 · Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical CancerEMD Serono Research & Development Institute, Inc. · completed · Uterine Cervical Neoplasms · study director
- Ph1NCT04204902 · Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04170153 · Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)EMD Serono Research & Development Institute, Inc. · completed · Metastatic or Locally Advanced Unresectable Solid Tumors · study director
- Ph1NCT04132583 · Deflox Tablets Bioequivalence (BE) TrialMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT04075721 · First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneEMD Serono Research & Development Institute, Inc. · terminated · Multiple Myeloma · study director
- Ph2/Ph3NCT04066491 · Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTCEMD Serono Research & Development Institute, Inc. · terminated · Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer · study director
- Ph1NCT04037748 · Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet FormMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph3NCT04032158 · Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)EMD Serono Research & Development Institute, Inc. · terminated · Relapsing-remitting Multiple Sclerosis · study director
- Ph3NCT04032171 · Study of Evobrutinib in Participants With RMSEMD Serono Research & Development Institute, Inc. · terminated · Relapsing-remitting Multiple Sclerosis · study director
- Ph1NCT03979274 · A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy VolunteersMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT03962543 · MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · active not recruiting · Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) · study director
- Ph4NCT03961204 · Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)EMD Serono Research & Development Institute, Inc. · completed · Multiple Sclerosis (MS) · study director
- Ph2NCT03940703 · A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)EMD Serono Research & Development Institute, Inc. · completed · Non-small Cell Lung Cancer · study director
- Ph1NCT03934502 · Effect of Meal Composition and Timing on Evobrutinib BioavailabilityMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- N/ANCT03933202 · A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)EMD Serono Research & Development Institute, Inc. · completed · Multiple Sclerosis · study director
- N/ANCT03933215 · A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)EMD Serono Research & Development Institute, Inc. · completed · Multiple Sclerosis · study director
- Ph4NCT03858049 · Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)Merck KGaA, Darmstadt, Germany · terminated · Infertility · study director
- Ph3NCT03845140 · L-PZQ ODT in Schistosoma Infected ChildrenMerck KGaA, Darmstadt, Germany · completed · Schistosomiasis · study director
- Ph1/Ph2NCT03840915 · M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)EMD Serono Research & Development Institute, Inc. · completed · Carcinoma, Non-Small-Cell Lung · study director
- Ph2NCT03840902 · M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)EMD Serono Research & Development Institute, Inc. · terminated · Non-small Cell Lung Cancer · study director
- Ph2NCT03833661 · M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)EMD Serono Research & Development Institute, Inc. · completed · Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer · study director
- Ph3NCT03815643 · Avelumab Program Rollover StudyEMD Serono Research & Development Institute, Inc. · active not recruiting · Solid Tumors · study director
- Ph1/Ph2NCT03770689 · Study of Peposertib in Combination With Capecitabine and RT in Rectal CancerEMD Serono Research & Development Institute, Inc. · completed · Locally Advanced Rectal Cancer · study director
- Ph1NCT03745144 · Effects of Cladribine Tablets on the PK of Microgynon®Merck KGaA, Darmstadt, Germany · completed · Relapsing Multiple Sclerosis (RMS) · study director
- Ph1NCT03725072 · Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-EvobrutinibMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03724890 · Study of Avelumab-M3814 CombinationsEMD Serono Research & Development Institute, Inc. · completed · Oncology, Solid Tumors · study director
- Ph2NCT03717155 · Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCMerck KGaA, Darmstadt, Germany · completed · Squamous Non-Small Cell Lung Cancer · study director
- Ph1NCT03704467 · Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerEMD Serono Research & Development Institute, Inc. · completed · Ovarian Cancer · study director
- Ph1NCT03676322 · Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy ParticipantsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph3NCT03631706 · M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)EMD Serono Research & Development Institute, Inc. · completed · Non-small Cell Lung Cancer · study director
- Ph1NCT03629223 · Bioequivalence of TF3 and TF2 and Effect of Food on the PK of TepotinibMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03628339 · Effect of Tepotinib on PK of CYP3A Substrate MidazolamMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- N/ANCT03584321 · Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery DiseaseMerck KGaA, Darmstadt, Germany · completed · Non-Obstructive Coronary Artery Disease · study director
- Ph1NCT03583346 · Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)Merck KGaA, Darmstadt, Germany · completed · Osteoarthritis, Knee · study director
- Ph1NCT03583385 · Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) StudyMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03566810 · Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)Merck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03546608 · Tepotinib Hepatic Impairment TrialEMD Serono Research & Development Institute, Inc. · completed · Hepatic Impairment · study director
- Ph1NCT03531762 · Effect of a Proton Pump Inhibitor on the PK of TepotinibMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03523390 · Phase I/Ib Multiple Ascending Dose Study in ChinaMerck KGaA, Darmstadt, Germany · completed · Metastatic Solid Tumors · study director
- Ph1NCT03492437 · Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03467971 · A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy ParticipantsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03467945 · Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy ParticipantsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03451825 · Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsEMD Serono Research & Development Institute, Inc. · terminated · Refractory or Relapsed Solid Tumors, Lymphoma · study director
- Ph1NCT03436394 · Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)Merck KGaA, Darmstadt, Germany · completed · Renal Impairment · study director
- Ph1NCT03437447 · Praziquantel Bioequivalence StudyMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03393208 · Glucophage Immediate Release (GIR) China Bioequivalence StudyMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT03387046 · A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)Merck KGaA, Darmstadt, Germany · terminated · Multiple Sclerosis, Relapsing-Remitting · study director
- Ph4NCT03387059 · Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice ForielleMerck KGaA, Darmstadt, Germany · terminated · Infertility · study director
- Ph4NCT03369665 · Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)Merck KGaA, Darmstadt, Germany · completed · Multiple Sclerosis · study director
- Ph4NCT03364036 · Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)Merck KGaA, Darmstadt, Germany · completed · Multiple Sclerosis · study director
- Ph1NCT03309150 · ATRi Transition Rollover StudyMerck KGaA, Darmstadt, Germany · completed · Advanced Stage Solid Tumors · study director
- Ph1NCT03306420 · First-in-Human Study of MS201408-0005A as Single Agent and in CombinationsEMD Serono Research & Development Institute, Inc. · terminated · Metastatic or Locally Advanced Unresectable Solid Tumors · study director
- Ph1NCT03297983 · M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsuleMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- N/ANCT03284970 · Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesEMD Serono Research & Development Institute, Inc. · completed · Relapsing-Remitting Multiple Sclerosis · study director
- Ph1NCT03282851 · Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456Fresenius Kabi SwissBioSim GmbH · completed · Healthy · study director
- Ph1NCT03261401 · First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy ParticipantsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT03233230 · Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisEMD Serono Research & Development Institute, Inc. · completed · Rheumatoid Arthritis · study director
- Ph1NCT03224702 · First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy VolunteersMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03225105 · M3541 in Combination With Radiotherapy in Solid TumorsEMD Serono Research & Development Institute, Inc. · terminated · Solid Tumors · study director
- Ph1NCT03226275 · Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese ParticipantsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph4NCT03164551 · TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and AssessmentMerck KGaA, Darmstadt, Germany · terminated · Infertility · study director
- Ph1NCT03138538 · M8891 First in Human in Solid TumorsEMD Serono Research & Development Institute, Inc. · terminated · Advanced Solid Tumors, Metastatic Renal Cell Carcinoma · study director
- Ph1NCT03116971 · Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)EMD Serono Research & Development Institute, Inc. · terminated · Small Cell Lung Cancer · study director
- Ph3NCT03052322 · MSB11022 in Moderate to Severe Rheumatoid ArthritisFresenius Kabi SwissBioSim GmbH · completed · Moderate to Severe Rheumatoid Arthritis · study director
- Ph4NCT03026088 · Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure ParticipantsMerck KGaA, Darmstadt, Germany · terminated · Heart Failure · study director
- Ph1NCT03021642 · Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy VolunteersMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT03014947 · MSB11022 in Healthy SubjectsFresenius Kabi SwissBioSim GmbH · completed · Healthy Subjects · study director
- Ph4NCT03010423 · Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) ParticipantsMerck KGaA, Darmstadt, Germany · terminated · Non-obstructive Coronary Artery Disease · study director
- Ph1NCT02994953 · A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)EMD Serono Research & Development Institute, Inc. · terminated · Advanced Solid Tumors · study director
- Ph2NCT02975336 · A Phase II Study of M2951 in SLEEMD Serono Research & Development Institute, Inc. · terminated · Systemic Lupus Erythematosus · study director
- Ph2NCT02975349 · A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisEMD Serono Research & Development Institute, Inc. · terminated · Relapsing-remitting Multiple Sclerosis · study director
- N/ANCT02949908 · MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)Merck KGaA, Darmstadt, Germany · terminated · Multiple Sclerosis · study director
- N/ANCT02889380 · A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) TreatmentMerck KGaA, Darmstadt, Germany · completed · Infertility · study director
- Ph2NCT02864992 · Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD Serono Research & Development Institute, Inc. · active not recruiting · Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV · study director
- Ph2NCT02808429 · Efficacy and Safety of Atacicept in IgA NephropathyEMD Serono Research & Development Institute, Inc. · terminated · IgA Nephropathy · study director
- Ph2NCT02806232 · An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)Merck KGaA, Darmstadt, Germany · completed · Schistosomiasis · study director
- Ph2NCT02784106 · Safety and Efficacy Study of M2951 in Participants With Rheumatoid ArthritisEMD Serono Research & Development Institute, Inc. · completed · Rheumatoid Arthritis · study director
- Ph2NCT02745145 · Abituzumab in SSc-ILDEMD Serono Research & Development Institute, Inc. · terminated · Systemic Sclerosis-associated Interstitial Lung Disease · study director
- Ph1NCT02699515 · MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid TumorsMerck KGaA, Darmstadt, Germany · completed · Solid Tumors · study director
- Ph3NCT02660580 · MSB11022 in Moderate to Severe Chronic Plaque PsoriasisFresenius Kabi SwissBioSim GmbH · completed · Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis · study director
- Ph1NCT02644278 · First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With ChemotherapyEMD Serono Research & Development Institute, Inc. · completed · Advanced Solid Tumor · study director
- Ph3NCT02625610 · Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)EMD Serono Research & Development Institute, Inc. · completed · Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction · study director
- Ph3NCT02625623 · Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)EMD Serono Research & Development Institute, Inc. · completed · Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line · study director
- N/ANCT02607293 · A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian StimulationMerck KGaA, Darmstadt, Germany · completed · Polycystic Ovary Syndrome · study director
- Ph3NCT02576574 · Avelumab in First-line NSCLC (JAVELIN Lung 100)EMD Serono Research & Development Institute, Inc. · completed · First Line Non-Small Cell Lung Cancer · study director
- Ph1NCT02537028 · MSC2364447C Phase 1b in Systemic Lupus ErythematosusEMD Serono Research & Development Institute, Inc. · completed · Lupus Erythematosus, Systemic · study director
- Ph1NCT02517398 · MSB0011359C (M7824) in Metastatic or Locally Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · completed · Solid Tumors · study director
- Ph1NCT02516813 · Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With RadiotherapyEMD Serono Research & Development Institute, Inc. · completed · Advanced Solid Tumors · study director
- Ph4NCT02417441 · TiLE (Time Lapse Eeva) Clinical TrialMerck KGaA, Darmstadt, Germany · completed · Fertility · study director
- Ph3NCT02395172 · Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)EMD Serono Research & Development Institute, Inc. · completed · Carcinoma, Non-Small-Cell Lung · study director
- N/ANCT02394782 · Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)Merck KGaA, Darmstadt, Germany · terminated · Multiple Sclerosis, Relapsing-remitting · study director
- Ph3NCT02383966 · Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck CancerMerck KGaA, Darmstadt, Germany · completed · Carcinoma, Squamous Cell of Head and Neck · study director
- Ph1NCT02325713 · Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy VolunteersMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT02317809 · Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female SubjectsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT02316197 · Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaMerck KGaA, Darmstadt, Germany · completed · Advanced Solid Tumors, Chronic Lymphocytic Leukemia · study director
- Ph1NCT02315352 · Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 YearsMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph1NCT02278250 · First in Human Study of M4344 in Participants With Advanced Solid TumorsEMD Serono Research & Development Institute, Inc. · completed · Solid Tumor, Advanced Solid Tumor · study director
- Ph1NCT02271984 · Relative Bioavailability Trial of L-Praziquantel in Healthy VolunteersMerck KGaA, Darmstadt, Germany · completed · Healthy · study director
- Ph2NCT02255110 · A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaMerck KGaA, Darmstadt, Germany · terminated · Soft Tissue Sarcoma · study director
- Ph4NCT02254304 · Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™Merck KGaA, Darmstadt, Germany · completed · Relapsing Multiple Sclerosis, Clinically Isolated Syndrome · study director
- Ph4NCT02252965 · Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 DiabetesMerck KGaA, Darmstadt, Germany · completed · Diabetes Mellitus, Type 2 · study director
- Ph1NCT02157792 · M6620 First in Human StudyEMD Serono Research & Development Institute, Inc. · completed · Advanced Solid Tumor · study director
- Ph1NCT02156466 · Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis SubjectsMerck KGaA, Darmstadt, Germany · completed · Psoriasis · study director
- Ph2NCT02155647 · Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)EMD Serono Research & Development Institute, Inc. · completed · Carcinoma, Merkel Cell · study director
- Ph4NCT02117050 · RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateEMD Serono · terminated · Multiple Sclerosis · study director
- Ph1/Ph2NCT02115373 · c-Met Second-Line Hepatocellular CarcinomaMerck KGaA, Darmstadt, Germany · completed · Carcinoma, Hepatocellular · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.